Sangamo presents 'encouraging' ZFP therapeutic data at diabetes meeting

By Elaine Rigoli

Tampa, Fla., June 12 - Sangamo BioSciences, Inc. said Monday that encouraging phase 1b clinical data from its ZFP therapeutic program will be presented at the Scientific Sessions of the American Diabetes Association.

Sangamo is developing SB-509, a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF), designed to upregulate the expression of the gene encoding vascular endothelial growth factor, for the treatment of diabetic neuropathy.

In the presentation, researchers reported positive findings from Sangamo's phase 1a and 1b clinical trial in subjects with diabetic neuropathy, which demonstrated that a single treatment of SB-509 was well-tolerated and that no severe adverse events were observed.

Subjects in the phase 1b study and in the top dose cohorts of the phase 1a trial were treated within the pharmacologically effective dose range that had been demonstrated to be efficacious in preclinical animal studies, according to a news release.

"We expect to treat a further 18 subjects in our phase 1b study and are optimistically looking forward to initiating a phase 2 repeat-dosing study in the second half of this year," vice president of therapeutic development and chief medical officer Dale Ando said in the release.

Richmond, Calif.-based Sangamo BioSciences is focused on the research and development of DNA-binding proteins for therapeutic gene regulation and modification.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.